Avid Bioservices Inc (CDMO)

[sulaco]

EBS, the question is why the rotten cohort?


Yopp's open-label liver trial in advanced HCC had a rotten-to-the-core cohort.

You know that.

So what's PPHM's strategy? Well, what are you going to do, take a much better performance status cohort, and prove what?

Nothing. The size (n=38) is too small to prove much of anything in a healthy group. The study will also take too long.

PPHM wants fairly quick results that can allow them to move Bavi on to the next phase.

Yes, yes, it's terrible that Bavi didn't knock out a home-run. But if the baseball itself is in terrible condition, it won't go far anyway.

The liver trial WAS a base-hit, however, and that's all PPHM wanted.


Best,

Joe